OncoMethylome Sciences to Profile DNA for Abbott Oncology Compounds

18-Dec-2007

OncoMethylome Sciences entered into a pharmacogenomic service collaboration with Abbott. Under the terms of the collaboration, OncoMethylome will assist Abbott in profiling tumors. Specifically, OncoMethylome will be testing its DNA methylation biomarkers on Abbott's biological samples.

"We are very pleased to add this collaboration to existing similar agreements and to use our high-throughput methylation platform to efficiently test our methylation biomarkers on biological samples provided by Abbott", commented Dr. Jim DiGuiseppi, Chief Technology Officer of OncoMethylome. "We are pleased that Abbott has chosen OncoMethylome and our methylation technology for this collaboration"

Financial details of the agreement were not disclosed

Other news from the department business & finance

Most read news

More news from our other portals

Under the magnifying glass: The world of microscopy